Cited by 849Angiogenesis and VEGF in CancerCancer Immunotherapy and BiomarkersLymphatic System and Diseases

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Open access

Tian, Lin, Goldstein, Amit, Wang, Hai, Ching Lo, Hin, Sun Kim, Ik, Welte, Thomas, Sheng, Kuanwei, Dobrolecki, Lacey E., Zhang, Xiaomei, Putluri, Nagireddy, Phung, Thuy L., Mani, Sendurai A., Stossi, Fabio, Sreekumar, Arun, Mancini, Michael A., Decker, William K., Zong, Chenghang, Lewis, Michael T., Zhang, Xiang H.-F.·2017·Nature

DOI 10.1038/nature21724PMC PMC5788037

Open this paper in CoChat — free account

Abstract

Blockade of angiogenesis can retard tumour growth, but may also paradoxically increase metastasis. This paradox may be resolved by vessel normalization, which involves increased pericyte coverage, improved tumour vessel perfusion, reduced vascular permeability, and consequently mitigated hypoxia. Although these processes alter tumour progression, their regulation is poorly understood. Here we show that type 1 T helper (T H 1) cells play a crucial role in vessel normalization. Bioinformatic analyses revealed that gene expression features related to vessel normalization correlate with immunostimulatory pathways, especially T lymphocyte infiltration or activity. To delineate the causal relationship, we used various mouse models with vessel normalization or T lymphocyte deficiencies. Although disruption of vessel normalization reduced T lymphocyte infiltration as expected, reciprocal depletion or inactivation of CD4+ T lymphocytes decreased vessel normalization, indicating a mutually regulatory loop. In addition, activation of CD4+ T lymphocytes by immune checkpoint blockade increased vessel normalization. T H 1 cells that secrete interferon-γ are a major population of cells associated with vessel normalization. Patient-derived xenograft tumours growing in immunodeficient mice exhibited enhanced hypoxia compared to the original tumours in immunocompetent humans, and hypoxia was reduced by adoptive T H 1 transfer. Our findings elucidate an unexpected role of T H 1 cells in vasculature and immune reprogramming. T H 1 cells may be a marker and a determinant of both immune checkpoint blockade and anti-angiogenesis efficacy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature21724

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
REVIGO summarizes and visualizes long lists of gene ontology terms
Supek, F., Bošnjak, M., Škunca, N., & Šmuc, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021800 · Cited by 6,264
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases
Xie, C., Mao, X., Huang, J., Ding, Y., Wu, J., Dong, S., Kong, L., Gao, G., Li, C., & Wei, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr483 · Cited by 5,078
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922

Flagged first, then by citations

Show all 36 references

Sorted by citations

Items 401–500 of 849

Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer
Liang, L.-J., Hu, C., Wen, Y., Geng, X.-W., Chen, T., Gu, G.-Q., Wang, L., Xia, Y., Liu, Y., Fei, J., et al. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.296 · Cited by 17
Combined Blockade of GARP:TGF-β1 and PD-1 Increases Infiltration of T Cells and Density of Pericyte-Covered GARP+ Blood Vessels in Mouse MC38 Tumors
Bertrand, C., Meerbeeck, P. V., de Streel, G., Vaherto, N., Benhaddi, F., Rouaud, L., Noël, A., Coulie, P. G., van Baren, N., & Lucas, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.704050 · Cited by 17
Controlled platelet-derived growth factor delivery by hyaluronic acid hydrogels with tunable crosslinking for accelerated chronic wound healing
Qin, X., Yuan, H., Zhang, M., Liu, C., Yan, R., Song, H., & Dai, Q. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140710 · Cited by 16
Low-dose total body irradiation facilitates antitumoral Th1 immune responses
Sonanini, D., Griessinger, C. M., Schörg, B. F., Knopf, P., Dittmann, K., Röcken, M., Pichler, B. J., & Kneilling, M. (2021) · Theranostics · doi:10.7150/thno.61459 · Cited by 17
An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets
Dotse, E., Lim, K. H., Wang, M., Wijanarko, K. J., & Chow, K. T. (2022) · Life · doi:10.3390/life12020323 · Cited by 18
Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers
Shi, Y., Li, Y., Wu, B., Zhong, C., Lang, Q., Liang, Z., Zhang, Y., Lv, C., Han, S., Yu, Y., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108968 · Cited by 17
Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases
Yan, X., Qu, F., & Zhou, Y. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107322 · Cited by 19
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection
Anderson, T. S., McCormick, A. L., Daugherity, E. A., Oladejo, M., Okpalanwaka, I. F., Smith, S. L., Appiah, D., Wood, L. M., & Lowe, D. B. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2260620 · Cited by 16
Immune, metabolic landscapes of prognostic signatures for lung adenocarcinoma based on a novel deep learning framework
Qin, S., Sun, S., Wang, Y., Li, C., Fu, L., Wu, M., Yan, J., Wan, L., Lv, J., & Chen, L. (2024) · Scientific Reports · doi:10.1038/s41598-023-51108-x · Cited by 16
EnLIGHTenment of tumor vessel normalization and immunotherapy in glioblastoma
Treps, L. (2018) · The Journal of Pathology · doi:10.1002/path.5103 · Cited by 16
Fever-Inducible Lipid Nanocomposite for Boosting Cancer Therapy through Synergistic Engineering of a Tumor Microenvironment
Qu, D., Qin, Y., Liu, Y., Liu, T., Liu, C., Han, T., Chen, Y., Ma, C., & Li, X. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c06949 · Cited by 16
Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis
Xue, J.-S., Liu, H., Meng, G.-X., Ding, Z., Yan, L., Yao, S.-Y., Li, H.-C., Dong, Z., Chen, Z., Hong, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03103-2 · Cited by 16
Low-dose X-ray irradiation combined with FAK inhibitors improves the immune microenvironment and confers sensitivity to radiotherapy in pancreatic cancer
Chen, H., Tu, W., Lu, Y., Zhang, Y., Xu, Y., Chen, X., Zhu, M., & Liu, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113114 · Cited by 16
Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma
Yin, Z., Zhang, H., Zhang, K., Yue, J., Tang, R., Wang, Y., Deng, Q., & Yu, Q. (2025) · BMC Cancer · doi:10.1186/s12885-025-13801-0 · Cited by 16
Ultrasound cascade regulation of nano-oxygen hybrids triggering ferroptosis augmented sonodynamic anticancer therapy
Sun, Y. L., Wang, Y., Han, R., Ren, Z., Chen, X., Dong, W., Choi, S., Liu, Q., & Wang, X. (2023) · Nano Research · doi:10.1007/s12274-023-5377-0 · Cited by 15
SM22α+ vascular mural cells are essential for vessel stability in tumors and undergo phenotype transition regulated by Notch signaling
Zhang, X., Yan, X., Cao, J., Yang, Z., Cao, X., Zhang, Y., Liang, L., Zheng, M., Liu, X., Zhang, J., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01630-x · Cited by 16
Self-citation
Combination of Immunotherapy and Antiangiogenic Therapy in Cancer—a Rational Approach
Padda, S. K., & Reckamp, K. L. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.007 · Cited by 15
Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play
Donlon, N. E., Power, R. F., Hayes, C., Davern, M., Reynolds, J. V., & Lysaght, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031071 · Cited by 15
Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Niwa, Y., Adachi, K., Tabata, K., Ishida, R., Hotta, K., Ishida, T., Mano, Y., Ozawa, Y., Minoshima, Y., Funahashi, Y., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0475 · Cited by 15
Alternative Strategies to Inhibit Tumor Vascularization
Brossa, A., Buono, L., Fallo, S., Fiorio, A., Munaron, L., & Bussolati, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246180 · Cited by 15
Vascular reconstitution in the tumor for more effective tumor immunotherapy
Takakura, N. (2021) · Cancer Science · doi:10.1111/cas.14854 · Cited by 16
Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade
Blanchard, L., Vina, E., Ljubetic, J., Meneur, C., Tarroux, D., Baez, M., Marino, A. E., Ortéga, N., Knorr, D. A., Ravetch, J. V., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102141 · Cited by 14
Combine and conquer — antiangiogenic immunotherapy
Killock, D. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.65 · Cited by 14
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?
Fulgenzi, C. A. M., D’Alessio, A., Ogunbiyi, O., Demirtaş, C. Ö., Gennari, A., Cortellini, A., Sharma, R., & Pinato, D. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2072726 · Cited by 14
Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy
Meo, C., & de Nigris, F. (2024) · Cancers · doi:10.3390/cancers16030491 · Cited by 14
GraphMHC: Neoantigen prediction model applying the graph neural network to molecular structure
Jeong, H., Cho, Y.-R., Gim, J., Cha, S.-K., Kim, M., & Kang, D. R. (2024) · PLOS ONE · doi:10.1371/journal.pone.0291223 · Cited by 14
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer†
Armani, G., Madeddu, D., Mazzaschi, G., Bocchialini, G., Sogni, F., Frati, C., Lorusso, B., Falco, A., Lagrasta, C. A., Cavalli, S., et al. (2017) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx492 · Cited by 14
Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis
Zhen, Z., Shen, Z., Hu, Y., & Sun, P. (2021) · Aging · doi:10.18632/aging.203260 · Cited by 14
Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
Chen, Y., Liu, X., Huang, Z., Zhao, K., Wang, Y., Ren, F., Yu, J., & Meng, X. (2021) · Cancer Medicine · doi:10.1002/cam4.4363 · Cited by 14
Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
Sun, P., Wang, Y., Yang, H., Chen, C., Nie, M., Sun, X., He, X., Huang, K.-M., Huang, J., & Li, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.766200 · Cited by 14
T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker
Baxevanis, C. N., Gritzapis, A. D., Voutsas, I. F., Batsaki, P., Goulielmaki, M., Adamaki, M., Zoumpourlis, V., & Fortis, S. P. (2022) · Cancers · doi:10.3390/cancers14112674 · Cited by 15
Loss of Vascular Endothelial Glutaminase Inhibits Tumor Growth and Metastasis, and Increases Sensitivity to Chemotherapy
Ngwa, V. M., Edwards, D. N., Hwang, Y., Karno, B. A., Wang, X., Yan, C. W., Richmond, A. J., Brantley‐Sieders, D. M., & Chen, J. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0048 · Cited by 13
Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
Zhong, Y. M., Huo, H., Dai, S., & Su, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964779 · Cited by 14
Targeted Nanophotoimmunotherapy Potentiates Cancer Treatment by Enhancing Tumor Immunogenicity and Improving the Immunosuppressive Tumor Microenvironment
Li, K., Yang, D., & Liu, D. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00593 · Cited by 14
Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors
Mondino, A., Vella, G., & Icardi, L. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.006 · Cited by 14
Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy
Li, W., Zhan, M., Quan, Y., Wang, H., Hua, S., Li, Y., Zhang, J., Lu, L., & Cui, M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106227 · Cited by 14
Self-citation
Does immune checkpoint inhibitor exhibit limited efficacy against non‐viral hepatocellular carcinoma?: A review of clinical trials
Eso, Y., Taura, K., & Seno, H. (2021) · Hepatology Research · doi:10.1111/hepr.13712 · Cited by 14
Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors
Uyl, T. J. J., Ngo, A., Pratt, D., Cortez, I., Mathijssen, R. H. J., Versmissen, J., Danser, A. H. J., & Colafella, K. M. M. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00081.2025 · Cited by 13
Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications
Zhou, Z., Zhong, H., Wang, H., Wang, S., Kridis, W. B., Wang, R., Shen, K., Wang, Z., & Huang, R. (2025) · Discover Oncology · doi:10.1007/s12672-025-03797-1 · Cited by 17
Self-citation
Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer
Hu, M. X., Yao, W., & Shen, Q. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1005658 · Cited by 13
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
Huang, R., Bi, Z., Hu, S., Zhang, Q., Su, X., & Zhang, W. (2023) · Biomarker Research · doi:10.1186/s40364-023-00478-5 · Cited by 15
The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
Chen, S., Mo, W., Jiang, W., Zhou, S., Gan, H., & Yu, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1218258 · Cited by 13
Disturbed endothelial cell signaling in tumor progression and therapy resistance
Fischer, A., & Alsina‐Sanchís, E. (2023) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2023.102287 · Cited by 13
CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors
Sun, Y., Yee, E. J., Fujiwara, Y., Dickinson, K., Guo, Y., Sun, Z., Hu, J., Dávila, E., Schulick, R. D., & Zhu, Y. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010554 · Cited by 13
Cancer Stem Cells and Combination Therapies to Eradicate Them
Tang, Q., Yin, D., Wang, Y., Du, W., Qin, Y., Ding, A., & Li, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200406083756 · Cited by 13
Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors
Yuan, W., Xiao, C., Lao, X., Zheng, L., & Kuang, D. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03637-1 · Cited by 13
Angiogenesis in biliary tract cancer: targeting and therapeutic potential
Rimini, M., & Gardini, A. C. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1881479 · Cited by 13
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
D’Alessio, A., Cammarota, A., Zanuso, V., Pressiani, T., Personeni, N., & Rimassa, L. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1948329 · Cited by 13
Introduction of Mutant GNAQ into Endothelial Cells Induces a Vascular Malformation Phenotype with Therapeutic Response to Imatinib
Sasaki, M., Jung, Y., North, P. E., Elsey, J., Choate, K. A., Toussaint, M. A., Huang, C. Y., Radi, R., Perricone, A. J., Corces, V. G., et al. (2022) · Cancers · doi:10.3390/cancers14020413 · Cited by 13
Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts
Wang, H., Li, Z., Ou, S., Song, Y., Luo, K., Guan, Z., Zhao, L., Huang, R., & Yu, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.884839 · Cited by 13
Self-citation
A Hybrid Discrete–Continuum Modelling Approach to Explore the Impact of T-Cell Infiltration on Anti-tumour Immune Response
de Almeida, L. N., Audebert, C., Leschiera, E., & Lorenzi, T. (2022) · Bulletin of Mathematical Biology · doi:10.1007/s11538-022-01095-3 · Cited by 13
Metformin enhances T lymphocyte anti-tumor immunity by increasing the infiltration via vessel normalization
Li, G., Feng, Y.-Q., Jia, Y., Wang, K.-F., Li, Y., Zhang, S., Han, S., & Wang, J. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175592 · Cited by 13
TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial
Qi, W., Peng, W. J., Qi, X., Qiu, Z., Wen, T., & Li, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1138570 · Cited by 13
DC101, an anti-VEGFR2 agent, promotes high-endothelial venule formation and immune infiltration versus SAR131675 and fruquintinib
Wang, Z., Shi, X., Zhao, Y., Zhou, J., Zhang, S., Wang, J., Yu, W., Zhang, X., Ren, X., & Zhao, H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.018 · Cited by 12
Self-citation
Pan‐cancer efficacy and safety of anlotinib plus PD ‐1 inhibitor in refractory solid tumor: A single‐arm, open‐label, phase II trial
Qin, B., Jiao, X., Wang, Z., Liu, K., Wu, Y., Ling, Y., Chen, S., Zhong, X., Duan, X., Qin, W., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34546 · Cited by 12
Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer
Lin, Q.-X., Song, W.-W., Xie, W.-X., Deng, Y., Gong, Y.-N., Liu, Y., Tian, Y., Zhao, W.-Y., Tian, L., & Gu, D.-N. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101077 · Cited by 12
Self-citation
Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies
Arandhara, A., Bhuyan, P., & Das, B. K. (2025) · Discover Oncology · doi:10.1007/s12672-025-01902-y · Cited by 12
Angiogenesis and immune microenvironment in triple-negative breast cancer: Targeted therapy
Zhang, Y., Yang, H., Jiang, Y., Jiang, Y., & Mao, R. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167880 · Cited by 16
CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer
Zheng, X., Xu, H., Lin, T., Tan, P., Xiong, Q., Yi, X., Qiu, S., Yang, L., Shen, B., Ai, J., et al. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105727 · Cited by 12
Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer
Jiang, Y., Huang, S., Zhu, X., Liang Cheng, C., Liu, W., Chen, Q., & Yang, D. (2022) · Journal of Oncology · doi:10.1155/2022/8213321 · Cited by 12
Angiogenesis and Immunosuppressive Niche in Hepatocellular Carcinoma: Reshaping Vascular - Immune Axis to Potentiate antiPD - 1/PD - L1 Therapy
Li, W., Li, G., Luo, C.-S., Yu, Q., & Cui, M. (2025) · Cancer Management and Research · doi:10.2147/cmar.s537930 · Cited by 11
Neutrophils in non-small cell lung cancer and immunotherapy with PD-1/PD-L1 inhibitors
Hu, S., Yan, C., Tian, Y., & Sun, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07084-z · Cited by 11
IFNγ-dependent metabolic reprogramming restrains an immature, pro-metastatic lymphatic state in melanoma
Karakousi, T. R., Cristaldi, V., de Oliveira, M. L. L., Delclaux, I., Besson, N. R., Geraldo, L. H., González-Robles, T. J., McDonnough, D. R., Martinez-Krams, D., Silva, G., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.12.019 · Cited by 12
A bibliometric analysis of the research landscape on vascular normalization in cancer
Xie, H., Wang, S., Niu, D., Yang, C., Bai, H., Lei, T., & Liu, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29199 · Cited by 11
PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination
Franzolin, G., Brundu, S., Cojocaru, C. F., Curatolo, A., Ponzo, M., Mastrantonio, R., Mihara, E., Kumanogoh, A., Suga, H., Takagi, J., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0289 · Cited by 13
Cancer Immunotherapy with “Vascular-Immune” Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems
Jiang, Z., Fang, Z., Hong, D., & Wang, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s467222 · Cited by 12
Single‐cell transcriptomic analysis of glioblastoma reveals pericytes contributing to the blood–brain–tumor barrier and tumor progression
Li, Y., Wu, C., Long, X., Wang, X., Gao, W., Deng, K., Xie, B., Zhang, S., Wu, M., & Liu, Q. (2024) · MedComm · doi:10.1002/mco2.70014 · Cited by 11
Immunochemotherapy plus radiotherapy versus immunochemotherapy alone as first-line treatment for treatment-naïve, advanced esophageal squamous cell carcinoma (AEC-ICR-1st): A multi-center cohort study
Li, J., Wang, X., Cao, J., Fan, C., Xiao, Q., Zheng, Z., Gao, W., Liu, X., Feng, P., Liu, F., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217411 · Cited by 11
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial
Chu, T., Zhong, H., Yu, Z., Wang, J., Zhao, Y., Mu, X., Yu, X., Shi, X., Shi, Q., Guan, M., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.12654 · Cited by 11
The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma
Liu, L., Qin, S., & Zhang, Y. (2021) · Targeted Oncology · doi:10.1007/s11523-020-00787-x · Cited by 11
Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy
He, M. Y., Halford, M. M., Liu, R., Roy, J. P., Grant, Z. L., Coultas, L., Thio, N., Gilan, O., Chan, Y.-C., Dawson, M. A., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02397-3 · Cited by 11
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials
Cammarota, A., Zanuso, V., D’Alessio, A., Pressiani, T., Personeni, N., & Rimassa, L. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2032641 · Cited by 11
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial
Li, R., Liu, X., Song, C., Zhang, W., Liu, J., Jiao, X., Yu, Y., Zeng, S., Chi, J., Zhao, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058132 · Cited by 11
The role of tumor neogenesis pipelines in tumor progression and their therapeutic potential
Fu, Z., & Yuan, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.4979 · Cited by 11
Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
Choi, S. W., Shin, H., Sa, J. K., Cho, H. J., Koo, H., Kong, D., Seol, H. J., & Nam, D. (2018) · Cancer Medicine · doi:10.1002/cam4.1439 · Cited by 11
Real‐world utilization of PD ‐1/ PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
Zhou, Z., Chen, K., Li, N., Xie, M., Sheng, J., Fan, Y., & Huang, Z. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14553 · Cited by 13
PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
Chen, S., Wei, H., Zhao, W., Jiang, W., Ning, R., Zhou, S., Tan, L., Wang, H., Su, C., He, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059995 · Cited by 11
Self-citation
T Peripheral Helper Cells in Lymphoid Aggregate and Tertiary Lymphoid Structure Formation
Sowerby, J. M., Choi, J., & Rao, D. A. (2025) · Immunological Reviews · doi:10.1111/imr.70088 · Cited by 12
Recent progresses on radiotherapeutics-based treatment of cancer with two-dimensional nanomaterials
Luo, G., Li, Z., Zheng, J., Yang, H., Li, X., Guishan, X., & Duo, Y. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101584 · Cited by 10
Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions
Weishan, H., Dong-lin, Z., Guangmei, D., Liu, W., Wu, F., & Chen, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03337-9 · Cited by 10
Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7+CD8+ T-cell entry into HCC through high endothelial venules
Tang, L., Hou, Y., Di, T., Lu, X., Huang, J., Gu, L., Yu, Y., Liu, L., Qiu, J., Li, L., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001426 · Cited by 10
Self-citation
Resident Memory T Cells in the Tumor Microenvironment
Williams, J. B., & Kupper, T. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_3 · Cited by 11
Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma
Park, K. Y., Hefti, H., Liu, P., Lugo-Cintrón, K. M., Kerr, S. C., & Beebe, D. J. (2021) · Integrative Biology · doi:10.1093/intbio/zyab018 · Cited by 10
A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
Meyo, M. T., Chen, J., Goldwasser, F., Hirsch, L., & Huillard, O. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s263832 · Cited by 10
Vascular Disruptive Hydrogel Platform for Enhanced Chemotherapy and Anti-Angiogenesis through Alleviation of Immune Surveillance
Li, F., Shao, X., Liu, D., Jiao, X., Yang, X., Yang, W., & Liu, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091809 · Cited by 9
Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy
Chu, X., Bao, H., Lin, Y.-J., Chen, R., Zhang, Y., Huang, T., He, J., Huangfu, S., Pan, Y., & Ding, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965492 · Cited by 10
IFNγ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins
Wang, R., Ni, C., Lou, X., Zhang, L., Wang, L., Yao, X., Duan, X., Wan, J., Li, P., & Qin, Z. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78248 · Cited by 10
A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma
Liu, Y., Wang, J., Shen, X., Li, L., Zhang, N., Wang, X., & Tang, B. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01127-9 · Cited by 10
Glioblastoma Vascular Plasticity Limits Effector T-cell Infiltration and Is Blocked by cAMP Activation
Qin, Z., Huang, Y., Li, Z., Pan, G., Zheng, L., Xiao, X., Wang, F., Chen, J., Chen, X., Lin, X., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0872 · Cited by 10
Update on Radiotherapy Changes of Nasopharyngeal Carcinoma Tumor Microenvironment
Zhu, D., Su, C., Li, J. J., Li, A. W., Luv, Y., & Fan, Q. (2023) · World Journal of Oncology · doi:10.14740/wjon1645 · Cited by 10
PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response
Ansardamavandi, A., Nikfarjam, M., & He, H. Z. (2023) · Cells · doi:10.3390/cells12232692 · Cited by 10
First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
Zhou, Y., Long, Y., Chen, Y., Liu, J., Pu, D., Huang, J., Bi, F., Li, Q., Gou, H., & Qiu, M. (2021) · Cancer Medicine · doi:10.1002/cam4.3876 · Cited by 10
Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report
Luo, Z., Zhang, H., Xiao, Y., Wang, R., Zhang, L., Huang, C., Cao, Y. Q., Sun, C., Zhao, Y., Lin, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633446 · Cited by 10
Esterase D stabilizes FKBP25 to suppress mTORC1
Yang, Y., Chen, X., Yao, W., Cui, X., Li, N., Lin, Z., Zhao, B., & Miao, J. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00297-2 · Cited by 10
Tumour vessel normalization and immune checkpoint blockade: a new synergism
Ganß, R. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.30 · Cited by 10
Intratumoral CCR5 + neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses
Xiang, Z., Zhou, Q., Zeng, H., Wang, Z., Zhang, H., Liu, Z., Huang, Q., Chang, Y., Bai, Q., Xia, Y., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1802176 · Cited by 10
Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib
Lu, Y., Jin, J., Du, Q., Hu, M. S., Wei, Y., Wang, M., Li, H., & Li, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.730240 · Cited by 12
Efficacy and safety of immunoradiotherapy for advanced non-small cell lung cancer: a retrospective comparative cohort study
Gao, Y., Sun, X., Hou, Y., Zhang, M., Tan, W., Zhang, Y., Wang, J., Zheng, Z., Li, C., Qi, H., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1685 · Cited by 10
Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer
Yin, G., Liu, X., Yu, X., Tan, S., & Liu, F. (2025) · Scientific Reports · doi:10.1038/s41598-024-83947-7 · Cited by 9
Benign non-immune cells in tumor microenvironment
Liu, S., Liu, C., He, Y., & Li, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561577 · Cited by 9

Authors: Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., Phung, T. L., Mani, S. A., Stossi, F., Sreekumar, A., Mancini, M. A., Decker, W. K., Zong, C., Lewis, M. T., & Zhang, X. H.-F.
Affiliations: Baylor College of Medicine (US)
The University of Texas MD Anderson Cancer Center (US)
Corresponding author: Zhang, Xiaomei
Zhang, Xiang H.-F.
ORCID: Tian, Lin
Goldstein, Amit
Wang, Hai
Welte, Thomas
Sheng, Kuanwei
Dobrolecki, Lacey E.
Zhang, Xiaomei
Putluri, Nagireddy
Phung, Thuy L.
Mani, Sendurai A.
Stossi, Fabio
Sreekumar, Arun
Mancini, Michael A.
Decker, William K.
Zong, Chenghang
Lewis, Michael T.
Zhang, Xiang H.-F.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2017-04
Volume: 544
Issue: 7649
Pages: 250-254
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature21724
PMC: PMC5788037
OpenAlex: W2601414401
Cited by: 841
References: 36
Citations by year: 2026: 88 · 2025: 98 · 2024: 98 · 2023: 100 · 2022: 92 · 2021: 129 · 2020: 97 · 2019: 63 · 2018: 51 · 2017: 25
FWCI: 26.46
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: National Institutes of Health (1s10od016167-01)
National Cancer Institute (R00CA151293, R01CA220297, K99CA151293, R21CA185516, U01CA179674, R01CA183878, P30CA125123)
National Institute of Allergy and Infectious Diseases (P30AI036211, R01AI127387)
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056338)
National Center for Research Resources (S10RR024574)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords: tumor immunosuppression, pericyte coverage, tumor hypoxia, CD4+ T cells, Th1 cells, interferon-gamma, immune checkpoint blockade, anti-angiogenic therapy, T cell infiltration, endothelial cells, tumor vasculature, patient-derived xenografts, cancer immunotherapy
MeSH terms: Animals, Capillary Permeability, Female, Humans, Interferon-gamma, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Neovascularization, Pathologic, Prognosis, CD4-Positive T-Lymphocytes, Cell Hypoxia, Lymphocytes, Tumor-Infiltrating, Th1 Cells, Neovascularization, Physiologic, Adoptive Transfer, Pericytes, Xenograft Model Antitumor Assays, Endothelial Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks